Viridian Therapeutics Elegrobart Achieves 50-54% Proptosis And 61% Diplopia Responder Rates In Phase 3 REVEAL-2, Becoming Only Subcutaneous Program With Two Positive TED Pivotal Trials

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

VRDN

0.00

- REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect -

- Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statistically significant results (p < 0.0001) -

- Elegrobart Q4W achieved a statistically significant 61% diplopia responder rate at week 24, versus 38% placebo (p = 0.0118) -

- Elegrobart was generally well tolerated in both dose groups, with a safety profile consistent with REVEAL‑1 and low rates of hearing impairment -

- Elegrobart is the only subcutaneous program to demonstrate positive phase 3 data in both active and chronic TED pivotal clinical trials and has the potential to be the first autoinjector treatment for TED; BLA submission on track for Q1 2027 -

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.